Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I am interested/surprised that there does not seem

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155537
(Total Views: 826)
Posted On: 07/30/2020 9:13:57 AM
Posted By: blafarm
Re: CTMedic #45918
Quote:
I am interested/surprised that there does not seem to be any use of leronlimab in MIS-C. Has anyone seen reports of this? Cytodyn offered free chemokine analysis of MIS-C, presumably with Incelldx panel, but I have not heard of any availing themselves of this opportunity.

I don't believe we've heard an update on this, just as surprised as you.

This is all I have:

5/13/2020 Notes (can't guaranteed accuracy):
Quote:
Protocols being submitted for children with Kawasaki-like symptoms soon – there are hurdles
The Kawasaki-like protocol will likely consist of three doses, the first by IV infusion



5/15/2020 Press Release:
Source Link: https://seekingalpha.com/news/3574944-cytodyn...ent=link-1
Quote:
CytoDyn (OTCQB:CYDY) is offering comprehensive cytokine profiling through its diagnostic partner, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19.

These laboratory tests are exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children.

The condition resembles a rare childhood illness called Kawasaki disease, which has similar signs and symptoms and can lead to enlargement of blood vessels that in severe forms may cause heart damage.



5/17/2020 Notes (can't guaranteed accuracy):
Quote:
CytoDyn has no clinical pediatric studies for leronlimab, so they don’t feel they can ask the FDA for a Compassionate Use program. However, they do want to support pediatricians and institutions that are caring for these children. They may be filing for a Pediatric EIND. The recently announced free testing program is all about measuring RANTES in this cohort. With the number of hospitals now participating in trials, one would think it wouldn't be that difficult to obtain blood samples to prove the existence of RANTES – or not.



(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us